Where Does Wall Street Think Bolt Biotherapeutics Inc (BOLT) Stock Will Go?

Wall Street is positive on Bolt Biotherapeutics Inc (BOLT). On average, analysts give the stock a Buy rating. The average price target is $8.666, which means analysts expect the stock to climb by 293.91% over the next twelve months. That average ranking earns the stock an Analyst Rating of 23, which is better than 23% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating BOLT a Buy today. Find out what this means to you and get the rest of the rankings on BOLT!

See Full BOLT Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Bolt Biotherapeutics Inc Stock Today?

Bolt Biotherapeutics Inc (BOLT) stock is lower by -3.08% while the S&P 500 has risen 0.44% as of 3:57 PM on Monday, Aug 15. BOLT has fallen -$0.07 from the previous closing price of $2.27 on volume of 138,396 shares. Over the past year the S&P 500 has fallen -4.03% while BOLT has fallen -82.66%. BOLT lost -$2.60 per share the over the last 12 months. Click Here to get the full Stock Report for Bolt Biotherapeutics Inc stock.